Survivin Splice Variant 2β Enhances Pancreatic Ductal Adenocarcinoma Resistance to Gemcitabine

Ryan N. Fuller, Janviere Kabagwira, Paul A. Vallejos, Andrew D. Folkerts, Nathan R. Wall

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)1147-1160
Number of pages14
JournalOncoTargets and Therapy
Volume15
DOIs
StatePublished - 2022

ASJC Scopus Subject Areas

  • Oncology
  • Pharmacology (medical)

Keywords

  • FOLFIRINOX
  • Gemcitabine
  • chemoresistance
  • siRNA
  • survivin splice variants

Cite this